A case of malignant phyllodes tumor that responded to pazopanib and developed pneumothorax.
A case of malignant phyllodes tumor that responded to pazopanib and developed pneumothorax.
复制标题
一例对帕唑帕尼有反应并出现气胸的恶性叶状肿瘤。
DOI：
10.1007/s13691-022-00572-9
复制
发表时间：
2023
期刊：
影响因子：
--
通讯作者：
Horiuchi T.
中科院分区：
文献类型：
--
作者：
Ohmura H;Masuda T;Mimori K;Baba E;Horiuchi T.
在这里，我们提出了一个59岁的女性复发性恶性叶状肿瘤与多个肺和淋巴结转移谁制定了气胸后，帕唑帕尼管理。患者接受帕唑帕尼作为二线化疗。治疗2.5个月后，计算机断层扫描（CT）显示肺部病变的大小和空洞缩小;然而，新观察到左侧气胸。胸部正位X线片难以鉴别气胸。未观察到气胸的典型症状或体征，如呼吸困难、胸痛或呼吸音减弱。由于气胸较小且无症状，因此停止帕唑帕尼给药，并进行随访胸部X线和CT检查。1周后，CT显示气胸改善。化疗转换为艾日布林;然而，首次给予艾日布林后观察到肺部病变大小迅速增加，重新引入帕唑帕尼。经胸部X线及电脑断层追踪，气胸并未复发。
Here, we present a 59-year-old female with recurrent malignant phyllodes tumor with multiple lung and lymph node metastases who developed a pneumothorax after the administration of pazopanib. The patient received pazopanib as the second-line chemotherapy. After 2.5 months of the therapy, computed tomography (CT) showed a decrease in the sizes and cavitation of lung lesions; however, a left pneumothorax was newly observed. It was difficult to distinguish the pneumothorax by upright chest X-ray. Typical symptom or physical finding of pneumothorax, such as dyspnea, chest pain or decreased breath sound was not observed. As the pneumothorax was small and asymptomatic, the administration of pazopanib was discontinued and follow-up chest X-ray and CT were performed. After 1 week, CT showed an improvement in the pneumothorax. Chemotherapy was switched to eribulin; however, a rapid increase in sizes of lung lesions was observed after the first administration of eribulin, pazopanib was reintroduced. Careful follow-up by chest X-ray and CT was performed and the pneumothorax has not recurred.